132 related articles for article (PubMed ID: 31473933)
1. Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.
Udd KA; Bujarski S; Wirtschafter E; Spektor TM; Ghermezi M; Rassenti LZ; David ME; Nosrati JD; Rahbari AA; Wang J; Vardanyan S; Harutyunyan NM; Linesch J; Li M; Sanchez E; Chen H; Kipps TJ; Berenson JR
Target Oncol; 2019 Oct; 14(5):551-561. PubMed ID: 31473933
[TBL] [Abstract][Full Text] [Related]
2. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.
Soof CM; Spektor TM; Parikh SA; Slager SL; Rabe KG; Call TG; Kenderian SS; Ding W; Muchtar E; Ghermezi M; Kay NE; Berenson JR
Exp Hematol; 2022 Jul; 111():32-40. PubMed ID: 35525334
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker.
Sanchez E; Tanenbaum EJ; Patil S; Li M; Soof CM; Vidisheva A; Waterman GN; Hekmati T; Tang G; Wang CS; Chen H; Berenson J
Expert Rev Mol Diagn; 2018 Apr; 18(4):319-329. PubMed ID: 29504446
[TBL] [Abstract][Full Text] [Related]
4. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
[TBL] [Abstract][Full Text] [Related]
5. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.
Nichols EM; Jones R; Watson R; Pepper CJ; Fegan C; Marchbank KJ
Oncotarget; 2015 Oct; 6(32):32669-80. PubMed ID: 26452134
[TBL] [Abstract][Full Text] [Related]
6. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
[TBL] [Abstract][Full Text] [Related]
8. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
[TBL] [Abstract][Full Text] [Related]
9. [Assessment of selected markers of apoptosis and angiogenesis in chronic lymphocytic leukemia].
Motyčková M; Smolej L; Andrýs C; Rezáčová V; Reháček V; Simkovič M; Belada D; Zák P
Vnitr Lek; 2013 Sep; 59(9):782-93. PubMed ID: 24073950
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia.
Reinisch W; Willheim M; Hilgarth M; Gasché C; Mader R; Szepfalusi S; Steger G; Berger R; Lechner K; Boltz-Nitulescu G
J Clin Oncol; 1994 Oct; 12(10):2146-52. PubMed ID: 7931486
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
Srivastava MD; Srivastava A; Srivastava BI
Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
[TBL] [Abstract][Full Text] [Related]
13. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
14. Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients.
Van Damme M; Crompot E; Meuleman N; Mineur P; Dessars B; El Housni H; Bron D; Lagneaux L; Stamatopoulos B
Epigenetics; 2014 Oct; 9(10):1374-81. PubMed ID: 25437053
[TBL] [Abstract][Full Text] [Related]
15. TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia.
Szymańska A; Bojarska-Junak A; Drobiecki A; Tomczak W; Roliński J; Hus M; Hus I
Arch Immunol Ther Exp (Warsz); 2019 Feb; 67(1):55-65. PubMed ID: 30196472
[TBL] [Abstract][Full Text] [Related]
16. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes.
Sherry B; Jain P; Chiu PY; Leung L; Allen SL; Kolitz JE; Rai KR; Barrientos J; Liang S; Hawtin R; Chiorazzi N
Immunol Res; 2015 Dec; 63(1-3):216-27. PubMed ID: 26478573
[TBL] [Abstract][Full Text] [Related]
18. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.
Ferrer G; Bosch R; Hodgson K; Tejero R; Roué G; Colomer D; Montserrat E; Moreno C
Br J Haematol; 2014 Feb; 164(4):570-8. PubMed ID: 24245956
[TBL] [Abstract][Full Text] [Related]
19. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
[No Abstract] [Full Text] [Related]
20. Anti-BCMA antibodies in the future management of multiple myeloma.
Gavriatopoulou M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
Expert Rev Anticancer Ther; 2019 Apr; 19(4):319-326. PubMed ID: 30810049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
